TY  - CONF

T1  - Abstract GS2-07: MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

JO  - General Session Abstracts

PY  - 2018/02/14

AU  - Schmid P

AU  - Zaiss M

AU  - Harper-Wynne C

AU  - Ferreira M

AU  - Dubey S

AU  - Chan S

AU  - Makris A

AU  - Nemsadze G

AU  - Brunt AM

AU  - Kuemmel S

AU  - Ruiz Cabrero I et al

ED  - 

DO  - DOI: 10.1158/1538-7445.sabcs17-gs2-07

PB  - American Association for Cancer Research

Y2  - 2024/12/27

ER  -